William Blair Has Positive Estimate for AXSM FY2024 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at William Blair boosted their FY2024 EPS estimates for shares of Axsome Therapeutics in a research report issued on Monday, January 13th. William Blair analyst M. Minter now expects that the company will post earnings of ($4.04) per share for the year, up from their previous estimate of ($4.13). The consensus estimate for Axsome Therapeutics' current full-year earnings is ($4.61) per share. William Blair also issued estimates for Axsome Therapeutics' Q4 2024 earnings at ($0.84) EPS, Q1 2025 earnings at ($0.95) EPS, Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at $0.11 EPS, FY2025 earnings at ($1.62) EPS and FY2026 earnings at $4.74 EPS.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating analysts' consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. During the same quarter in the prior year, the company posted ($1.32) earnings per share.

A number of other research analysts have also recently issued reports on the stock. StockNews.com upgraded shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Robert W. Baird boosted their price target on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $121.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Truist Financial increased their price target on Axsome Therapeutics from $150.00 to $180.00 and gave the stock a "buy" rating in a report on Monday. Finally, Royal Bank of Canada lifted their price objective on Axsome Therapeutics from $130.00 to $131.00 and gave the company an "outperform" rating in a report on Friday, October 4th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, Axsome Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $129.43.

Axsome Therapeutics Trading Down 0.1 %

Shares of AXSM stock traded down $0.06 on Thursday, reaching $93.69. The company had a trading volume of 1,162,759 shares, compared to its average volume of 1,025,046. The stock has a market cap of $4.54 billion, a PE ratio of -14.35 and a beta of 1.04. The company has a 50-day moving average of $92.24 and a 200-day moving average of $89.32. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $105.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its stake in shares of Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock worth $19,062,000 after buying an additional 27,534 shares during the last quarter. PDT Partners LLC bought a new stake in Axsome Therapeutics during the third quarter worth about $1,052,000. Pallas Capital Advisors LLC acquired a new position in Axsome Therapeutics during the fourth quarter valued at approximately $2,237,000. Captrust Financial Advisors acquired a new position in Axsome Therapeutics during the third quarter valued at approximately $514,000. Finally, BNP Paribas Financial Markets grew its stake in Axsome Therapeutics by 71.7% in the third quarter. BNP Paribas Financial Markets now owns 13,733 shares of the company's stock valued at $1,234,000 after purchasing an additional 5,737 shares in the last quarter. Institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.